BACKGROUND: Early exposure to complex dietary proteins may increase the risk of beta-cell autoimmunity and type 1 diabetes in children with genetic susceptibility. We tested the hypothesis that supplementing breast milk with highly hydrolyzed milk formula would decrease the cumulative incidence of diabetes-associated autoantibodies in such children. METHODS: In this double-blind, randomized trial, we assigned 230 infants with HLA-conferred susceptibility to type 1 diabetes and at least one family member with type 1 diabetes to receive either acasein hydrolysate formula or a conventional, cow's-milk-based formula (control) whenever breast milk was not available during the first 6 to 8 months of life. Autoantibodies to insulin, glutamic acid decarboxylase (GAD), the insulinoma-associated 2 molecule (IA-2), and zinc transporter 8 were analyzed with the use of radiobinding assays, and islet-cell antibodies were analyzed with the use of immunofluorescence, during a median observation period of 10 years (mean, 7.5). The children were monitored for incident type 1 diabetes until they were 10 years of age. RESULTS: The unadjusted hazard ratio for positivity for one or more autoantibodies in the casein hydrolysate group, as compared with the control group, was 0.54 (95% confidence interval [CI], 0.29 to 0.95), and the hazard ratio adjusted for an observed difference in the duration of exposure to the study formula was 0.51 (95% CI, 0.28 to 0.91). The unadjusted hazard ratio for positivity for two or more autoantibodies was 0.52 (95% CI, 0.21 to 1.17), and the adjusted hazard ratio was 0.47 (95% CI, 0.19 to 1.07). The rate of reported adverse events was similar in the two groups. CONCLUSIONS:Dietary intervention during infancy appears to have a long-lasting effect on markers of beta-cell autoimmunity--markers that may reflect an autoimmune process leading to type 1 diabetes. (ClinicalTrials.gov number, NCT00570102.).
RCT Entities:
BACKGROUND: Early exposure to complex dietary proteins may increase the risk of beta-cell autoimmunity and type 1 diabetes in children with genetic susceptibility. We tested the hypothesis that supplementing breast milk with highly hydrolyzed milk formula would decrease the cumulative incidence of diabetes-associated autoantibodies in such children. METHODS: In this double-blind, randomized trial, we assigned 230 infants with HLA-conferred susceptibility to type 1 diabetes and at least one family member with type 1 diabetes to receive either a casein hydrolysate formula or a conventional, cow's-milk-based formula (control) whenever breast milk was not available during the first 6 to 8 months of life. Autoantibodies to insulin, glutamic acid decarboxylase (GAD), the insulinoma-associated 2 molecule (IA-2), and zinc transporter 8 were analyzed with the use of radiobinding assays, and islet-cell antibodies were analyzed with the use of immunofluorescence, during a median observation period of 10 years (mean, 7.5). The children were monitored for incident type 1 diabetes until they were 10 years of age. RESULTS: The unadjusted hazard ratio for positivity for one or more autoantibodies in the casein hydrolysate group, as compared with the control group, was 0.54 (95% confidence interval [CI], 0.29 to 0.95), and the hazard ratio adjusted for an observed difference in the duration of exposure to the study formula was 0.51 (95% CI, 0.28 to 0.91). The unadjusted hazard ratio for positivity for two or more autoantibodies was 0.52 (95% CI, 0.21 to 1.17), and the adjusted hazard ratio was 0.47 (95% CI, 0.19 to 1.07). The rate of reported adverse events was similar in the two groups. CONCLUSIONS: Dietary intervention during infancy appears to have a long-lasting effect on markers of beta-cell autoimmunity--markers that may reflect an autoimmune process leading to type 1 diabetes. (ClinicalTrials.gov number, NCT00570102.).
Authors: H K Akerblom; S M Virtanen; J Ilonen; E Savilahti; O Vaarala; A Reunanen; K Teramo; A-M Hämäläinen; J Paronen; M-A Riikjärv; A Ormisson; J Ludvigsson; H-M Dosch; T Hakulinen; M Knip Journal: Diabetologia Date: 2005-04-19 Impact factor: 10.122
Authors: S M Virtanen; M G Kenward; M Erkkola; S Kautiainen; C Kronberg-Kippilä; T Hakulinen; S Ahonen; L Uusitalo; S Niinistö; R Veijola; O Simell; J Ilonen; M Knip Journal: Diabetologia Date: 2006-04-05 Impact factor: 10.122
Authors: M Kukko; T Kimpimäki; S Korhonen; A Kupila; S Simell; R Veijola; T Simell; J Ilonen; O Simell; M Knip Journal: J Clin Endocrinol Metab Date: 2005-02-15 Impact factor: 5.958
Authors: Janet M Wenzlau; Kirstine Juhl; Liping Yu; Ong Moua; Suparna A Sarkar; Peter Gottlieb; Marian Rewers; George S Eisenbarth; Jan Jensen; Howard W Davidson; John C Hutton Journal: Proc Natl Acad Sci U S A Date: 2007-10-17 Impact factor: 11.205
Authors: Frederick W Miller; Lars Alfredsson; Karen H Costenbader; Diane L Kamen; Lorene M Nelson; Jill M Norris; Anneclaire J De Roos Journal: J Autoimmun Date: 2012-06-25 Impact factor: 7.094
Authors: Amir-Babak Sioofy-Khojine; Jussi Lehtonen; Noora Nurminen; Olli H Laitinen; Sami Oikarinen; Heini Huhtala; Outi Pakkanen; Tanja Ruokoranta; Minna M Hankaniemi; Jorma Toppari; Mari Vähä-Mäkilä; Jorma Ilonen; Riitta Veijola; Mikael Knip; Heikki Hyöty Journal: Diabetologia Date: 2018-02-05 Impact factor: 10.122
Authors: Carmen P Wong; Linda P Nguyen; Sang K Noh; Tammy M Bray; Richard S Bruno; Emily Ho Journal: Immunol Lett Date: 2011-05-20 Impact factor: 3.685
Authors: Linnea Reinert-Hartwall; Jarno Honkanen; Harri M Salo; Janne K Nieminen; Kristiina Luopajärvi; Taina Härkönen; Riitta Veijola; Olli Simell; Jorma Ilonen; Aleksandr Peet; Vallo Tillmann; Mikael Knip; Outi Vaarala Journal: J Immunol Date: 2014-12-05 Impact factor: 5.422